Health · FDA
FDA Approves Sanofi’s Venglustat for Type 3 Gaucher Disease Symptoms
The once-daily pill, sold as Infilbray, is the first approved treatment for the neurological symptoms of the rare inherited disorder.

The Food and Drug Administration on Nov. 18 approved venglustat, sold as Infilbray, against nervous-system effects of type 3 Gaucher disease in adults and in children weighing at least 33 pounds, according to Pharmacy Times, NeurologyLive and Contemporary Pediatrics, which cited the agency’s announcement. Sanofi, through its Genzyme unit, makes the oral tablet. The outlets describe it as the first treatment for those symptoms.
Venglustat blocks an enzyme involved in building the fatty substance that accumulates in Gaucher disease, and it is able to cross the blood-brain barrier. Pharmacy Times quoted acting FDA Commissioner Kyle Diamantas saying that ability lets the drug reach the source of the buildup.
Approval rested on a 52-week phase 3 trial of 43 patients who had been on enzyme replacement therapy. They took either daily venglustat or the infused therapy. NeurologyLive and Contemporary Pediatrics reported that venglustat produced a statistically significant improvement on a combined measure of movement and cognitive scores, and that it met three of four key secondary endpoints. The outlets differ on some trial statistics, so this report leaves them out.
The label warns of suicidal thoughts and behavior, and of possible eye-lens clouding in children and harm to a fetus, the last two based on animal data. None of the reports gave a price or launch date.
Sources
- Pharmacy Times, Nov. 18, 2026, Gillian McGovern: approval, indication, FDA commissioner quote, label warnings <https://www.pharmacytimes.com/view/fda-approves-venglustat-first-treatment-for-neurological-symptoms-of-gd3>
- NeurologyLive, Nov. 19, 2026, Isabella Ciccone: trial design and primary result <https://www.neurologylive.com/view/fda-approves-venglustat-first-therapy-neurological-manifestations-type-3-gaucher-disease>
- Contemporary Pediatrics, Nov. 19, 2026, Morgan Ebert: age and weight criteria, trial endpoints <https://www.contemporarypediatrics.com/view/fda-approves-venglustat-for-neurological-symptoms-of-gd3>
This article was drafted with AI writing tools from the sources listed, checked by a review pass, supervised by the paper’s editors and published by Daniel Varrone. Corrections: editor@monochromechronicles.com
More from Health
Recommended Reading
About this story: Compiled by the The Monochrome Chronicles desk from the sources listed above. Our standards · Report an error · Follow on YouTube